Trial reportDrug and alcohol dependence2018
Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
Trial report in Drug and alcohol dependence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2020Guideline
- Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies.JAMA internal medicine · 2026Article
- Health and Economic Impact of Periodic Hepatitis C Virus Testing Among People Who Inject Drugs.JAMA health forum · 2025Article
- Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Populations.Journal of viral hepatitis · 2025Article
- Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Modeling the impact of a supervised consumption site on HIV and HCV transmission among people who inject drugs in three counties in California, USA.The International journal on drug policy · 2024Article
- Estimating Joint Health State Utility Algorithms Under Partial Information.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Article
- Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.American journal of preventive medicine · 2023Article
- Formal Hepatitis C Education Increases Willingness to Receive Therapy in an On-site Shelter-Based HCV Model of Care in Persons Experiencing Homelessness.Open forum infectious diseases · 2022Article
- Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.Drug and alcohol dependence · 2022Article
- Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.PloS one · 2021Article
- Time for a New Approach to Guidance for Human Immunodeficiency Virus and Hepatitis C Virus Testing Among Persons Who Inject Drugs.The Journal of infectious diseases · 2020Article
- Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.Addiction (Abingdon, England) · 2020Article
- Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Opioid epidemic and liver disease.JHEP reports : innovation in hepatology · 2019Review
- Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.PloS one · 2019Article
- HIV, HBV and HCV in people who inject drugs and are placed on methadone maintenance therapy, Yangon, Myanmar.Public health action · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundWe evaluated the cost-effectiveness of a hepatitis C (HCV) screening and active linkage to care intervention in US methadone maintenance treatment (MMT) patients using data from a randomized trial conducted in New York City and San Francisco.
methodsWe used a decision analytic model to compare 1) no intervention; 2) HCV screening and education (control); and 3) HCV screening, education, and care coordination (active linkage intervention). We also explored an alternative strategy wherein HCV/HIV co-infected participants linked elsewhere. Trial data include population characteristics (67% male, mean age 48, 58% HCV infected) and linkage rates. Data from published sources include treatment efficacy and HCV re-infection risk. We projected quality-adjusted life years (QALYs) and lifetime medical costs using an established model of HCV (HEP-CE). Incremental cost-effectiveness ratios (ICERs) are in 2015 US$/QALY discounted 3% annually.
resultsThe control strategy resulted in a projected 35% linking to care within 6 months and 31% achieving sustained virologic response (SVR). The intervention resulted in 60% linking and 54% achieving SVR with an ICER of $24,600/QALY compared to no intervention from the healthcare sector perspective and was a more efficient use of resources than the control strategy. The intervention had an ICER of $76,500/QALY compared to the alternative strategy. From a societal perspective, the intervention had a net monetary benefit of $511,000-$975,600.
conclusionsHCV care coordination interventions that include screening, education and active linkage to care in MMT settings are likely cost-effective at a conventional $100,000/QALY threshold for both HCV mono-infected and HIV co-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.